

ANNEX IV

**CONCLUSIONS ON THE GRANTING OF THE CONDITIONAL MARKETING
AUTHORISATION PRESENTED BY THE EUROPEAN MEDICINES AGENCY**

Conclusions presented by the European Medicines Agency on:

- **Conditional marketing authorisation**

The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the conditional marketing authorisation as further explained in the European Public Assessment Report.